BAS – Beijing Atherosclerosis Study

Principal contacts

Zhi-Yong Zou - Peking University, Beijing, China

Study design

The Beijing Atherosclerosis Study (BAS) is a two-arm clinical trial based in Beijing, China. The principal aim of the trial was to investigate the effect of Lutein (20mg/day) versus Lutein (20mg/day) and Lycopene (20mg/day) on subclinical Atherosclerosis. Individuals were eligible for inclusion if they were aged between 45 and 68 years, owned Han nationality, and had early atherosclerosis. All procedures involving human subjects were approved by the medical ethics committee of Peking University. Written informed consent was obtained from each participant before participation in the study.

Link to study webpage –


Key publications

Effects of lutein and lycopene on carotid intima–media thickness in Chinese subjects with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. Br J Nutr. 2014 Feb;111(3):474-80